🔗 Share this article

A senior medical officer has been removed from participation in a major research project on puberty blockers after accusations of partiality surfaced.

Reported Involvement Led to Trial Halt

As reported by news accounts, Professor Jacob George, the chief medical director for the regulatory agency, expressed issues which resulted in the suspension of the national research initiative during early 2024.

This authority announced this weekend how George was recusing himself of involvement in the study after gender-critical online posts made previously came to light.

Nature of Online Posts

Among a post, he referred to author J.K. Rowling being a “treasure of our time.” In another, he stated that “the denial to accept fundamental scientific reality was worrisome” in regards to questions about an Olympic athlete’s gender.

This agency said how while the posts were posted prior to his role began, the official had been removed of oversight with the trial as an preventative measure.

Details of the Halted Clinical Trial

The Pathways trial, that was intended to evaluate the impact of puberty blockers for children exploring their gender identity, was due to commence recruiting volunteers during January.

Yet, the trial was halted in the following month once the regulatory body expressed worries about the safety of adolescents participating.

• The youngest subjects were projected to be 10 to 11 among biological females and eleven to twelve for boys.
• Its research team said previously how the strict screening procedure indicated those enrolled would almost certainly be of a higher age.
• But, the regulator has now recommended the lowest age limit should be fourteen owing to the unknown danger” for “long-term health consequences.”

The clinical trial aimed to recruit a projected 226 youths over the coming 36 months.

Background and a Independent Report

This study was commissioned following a recommendation from the Cass review into youth gender care, that found that the standard of the research purporting to show the advantages of this type of medication for adolescents experiencing gender incongruence were low-quality.”

Dr Hilary Cass, who headed that review, had earlier stated her report revealed a notably limited body of research” for the efficacy of such treatments.

Dr. Cass added, since there are medical professionals, young people as well as parents who are convinced passionately in the positive outcomes, a trial was the sole method forward to understand the situation.”

Expert Concern of the Action

Doctor Max Davie, an expert in adolescent medicine, said there was no convincing medical rationale to suspend the study.

“The social media posts by Prof George give a transparent view into his individual stance regarding gender identity,” Dr. Davie said. “The professor is free to hold any opinions about gender identity he may, however what he cannot do would be to let these views to impact the execution of his official role.”

He concluded: “For clarity, there exists no compelling medical basis to halt the Pathways trial. While Prof George’s own views are not the only potential reason for the regulator’s sudden change of position, it are the sole instance where we possess proof.”

Agency Statement and Future Actions

A regulatory representative stated: “In every medical studies, our primary concern remains the protection as well as wellbeing for the trial participants. As part of that commitment, complicated studies remain constantly under review and the MHRA keeps an active scientific dialogue alongside study funders.”

“We have leading medical, scientific and regulatory experts who work in a multidisciplinary group to provide evidence-based decisions on clinical trials. These experts are continuing to meet alongside the organizers to navigate the subsequent actions constructively.”

“After the finding regarding online activity posted prior to his appointment, Prof Jacob George is recused from any additional participation on this study as a precaution.”